Baron, Frédéric http://orcid.org/0000-0002-2944-3812
Ngoya, Maud http://orcid.org/0000-0002-7810-6900
Labopin, Myriam http://orcid.org/0000-0003-4514-4748
Cornelissen, Jan J.
Ganser, Arnold
Forcade, Edouard http://orcid.org/0000-0002-8873-2868
Sengeloev, Henrik
Socié, Gérard http://orcid.org/0000-0002-2114-7533
Blaise, Didier http://orcid.org/0000-0002-5684-9447
Bornhäuser, Martin
Valerius, Thomas
Reinhardt, Hans Christian
Kröger, Nicolaus http://orcid.org/0000-0001-5103-9966
Ruggeri, Annalisa http://orcid.org/0000-0002-7261-2765
Nagler, Arnon http://orcid.org/0000-0002-0763-1265
Mohty, Mohamad http://orcid.org/0000-0002-7264-808X
Article History
Received: 11 April 2021
Revised: 29 May 2021
Accepted: 21 June 2021
First Online: 10 July 2021
Competing interests
: FB has received travel grants and/or speaker honoraria from Celgene, AbbVie, Novartis, Pfizer, and Sanofi. HCR received consulting and lecture fees from Abbvie, AstraZeneca, Vertex and Merck. HCR received research funding from Gilead Pharmaceuticals. HCR is a co-founder of CDL Therapeutics GmbH. The other authors declare that they have no relevant conflict of interest in relation to this study.
: The scientific board of the ALWP of the EBMT approved this study. All patients gave informed consent to participate in retrospective studies.